| ISIN | LU0432979614 |
|---|---|
| Valor Number | 10261626 |
| Bloomberg Global ID | |
| Fund Name | JPM Global Healthcare Fund A acc USD |
| Fund Provider |
J.P. Morgan Bank Luxembourg S.A.
6, route de Trèves L-2633, Senningerberg Grand Duchy of Luxembourg |
| Fund Provider | J.P. Morgan Bank Luxembourg S.A. |
| Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
| Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
| Asset Class | Equities |
| EFC Category | Equity Health Care |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
| Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
| Investment Strategy *** | To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. |
| Peculiarities |
| Current Price * | 527.52 USD | 18.12.2025 |
|---|---|---|
| Previous Price * | 527.84 USD | 17.12.2025 |
| 52 Week High * | 543.68 USD | 26.11.2025 |
| 52 Week Low * | 437.54 USD | 15.05.2025 |
| NAV * | 527.52 USD | 18.12.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 3,905,881,438 | |
| Unit/Share Assets *** | 1,009,609,061 | |
| Trading Information SIX | ||
| YTD Performance | +12.71% |
31.12.2024 - 18.12.2025
31.12.2024 18.12.2025 |
|---|---|---|
| YTD Performance (in CHF) | -1.23% |
31.12.2024 - 18.12.2025
31.12.2024 18.12.2025 |
| 1 month | +1.11% |
18.11.2025 - 18.12.2025
18.11.2025 18.12.2025 |
| 3 months | +11.99% |
18.09.2025 - 18.12.2025
18.09.2025 18.12.2025 |
| 6 months | +15.89% |
18.06.2025 - 18.12.2025
18.06.2025 18.12.2025 |
| 1 year | +9.65% |
18.12.2024 - 18.12.2025
18.12.2024 18.12.2025 |
| 2 years | +13.17% |
18.12.2023 - 18.12.2025
18.12.2023 18.12.2025 |
| 3 years | +13.64% |
19.12.2022 - 18.12.2025
19.12.2022 18.12.2025 |
| 5 years | +13.56% |
18.12.2020 - 18.12.2025
18.12.2020 18.12.2025 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Eli Lilly and Co | 7.51% | |
|---|---|---|
| AbbVie Inc | 6.52% | |
| Johnson & Johnson | 5.20% | |
| AstraZeneca PLC | 5.15% | |
| Merck & Co Inc | 4.86% | |
| Danaher Corp | 3.45% | |
| Medtronic PLC | 3.42% | |
| UnitedHealth Group Inc | 3.06% | |
| CVS Health Corp | 2.71% | |
| Novo Nordisk AS Class B | 2.48% | |
| Last data update | 30.11.2025 | |
| TER *** | 1.69% |
|---|---|
| TER date *** | 30.06.2025 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 1.50% |
| Ongoing Charges *** | 1.69% |
|
SRRI ***
|
|
| SRRI date *** | 30.11.2025 |